Cargando…
Cerebrospinal fluid lipidomic fingerprint of obstructive sleep apnoea in Alzheimer’s disease
BACKGROUND: Obstructive sleep apnoea (OSA) has a high prevalence in patients with Alzheimer’s disease (AD). Both conditions have been shown to be associated with lipid dysregulation. However, the relationship between OSA severity and alterations in lipid metabolism in the brains of patients with AD...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408111/ https://www.ncbi.nlm.nih.gov/pubmed/37550750 http://dx.doi.org/10.1186/s13195-023-01278-7 |
_version_ | 1785086114401353728 |
---|---|
author | Dakterzada, Farida Benítez, Iván D. Targa, Adriano Carnes, Anna Pujol, Montse Jové, Mariona Mínguez, Olga Vaca, Rafi Sánchez-de-la-Torre, Manuel Barbé, Ferran Pamplona, Reinald Piñol-Ripoll, Gerard |
author_facet | Dakterzada, Farida Benítez, Iván D. Targa, Adriano Carnes, Anna Pujol, Montse Jové, Mariona Mínguez, Olga Vaca, Rafi Sánchez-de-la-Torre, Manuel Barbé, Ferran Pamplona, Reinald Piñol-Ripoll, Gerard |
author_sort | Dakterzada, Farida |
collection | PubMed |
description | BACKGROUND: Obstructive sleep apnoea (OSA) has a high prevalence in patients with Alzheimer’s disease (AD). Both conditions have been shown to be associated with lipid dysregulation. However, the relationship between OSA severity and alterations in lipid metabolism in the brains of patients with AD has yet to be fully elucidated. In this context, we examined the cerebrospinal fluid (CSF) lipidome of patients with suspected OSA to identify potential diagnostic biomarkers and to provide insights into the pathophysiological mechanisms underlying the effect of OSA on AD. METHODS: The study included 91 consecutive AD patients who underwent overnight polysomnography (PSG) to diagnose severe OSA (apnoea-hypopnea index ≥ 30/h). The next morning, CSF samples were collected and analysed by liquid chromatography coupled to mass spectrometry in an LC-ESI-QTOF-MS/MS platform. RESULTS: The CSF levels of 11 lipid species were significantly different between AD patients with (N = 38) and without (N = 58) severe OSA. Five lipids (including oxidized triglyceride OxTG(57:2) and four unknown lipids) were significantly correlated with specific PSG measures of OSA severity related to sleep fragmentation and hypoxemia. Our analyses revealed a 4-lipid signature (including oxidized ceramide OxCer(40:6) and three unknown lipids) that provided an accuracy of 0.80 (95% CI: 0.71–0.89) in the detection of severe OSA. These lipids increased the discriminative power of the STOP-Bang questionnaire in terms of the area under the curve (AUC) from 0.61 (0.50–0.74) to 0.85 (0.71–0.93). CONCLUSIONS: Our results reveal a CSF lipidomic fingerprint that allows the identification of AD patients with severe OSA. Our findings suggest that an increase in central nervous system lipoxidation may be the principal mechanism underlying the association between OSA and AD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01278-7. |
format | Online Article Text |
id | pubmed-10408111 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104081112023-08-09 Cerebrospinal fluid lipidomic fingerprint of obstructive sleep apnoea in Alzheimer’s disease Dakterzada, Farida Benítez, Iván D. Targa, Adriano Carnes, Anna Pujol, Montse Jové, Mariona Mínguez, Olga Vaca, Rafi Sánchez-de-la-Torre, Manuel Barbé, Ferran Pamplona, Reinald Piñol-Ripoll, Gerard Alzheimers Res Ther Research BACKGROUND: Obstructive sleep apnoea (OSA) has a high prevalence in patients with Alzheimer’s disease (AD). Both conditions have been shown to be associated with lipid dysregulation. However, the relationship between OSA severity and alterations in lipid metabolism in the brains of patients with AD has yet to be fully elucidated. In this context, we examined the cerebrospinal fluid (CSF) lipidome of patients with suspected OSA to identify potential diagnostic biomarkers and to provide insights into the pathophysiological mechanisms underlying the effect of OSA on AD. METHODS: The study included 91 consecutive AD patients who underwent overnight polysomnography (PSG) to diagnose severe OSA (apnoea-hypopnea index ≥ 30/h). The next morning, CSF samples were collected and analysed by liquid chromatography coupled to mass spectrometry in an LC-ESI-QTOF-MS/MS platform. RESULTS: The CSF levels of 11 lipid species were significantly different between AD patients with (N = 38) and without (N = 58) severe OSA. Five lipids (including oxidized triglyceride OxTG(57:2) and four unknown lipids) were significantly correlated with specific PSG measures of OSA severity related to sleep fragmentation and hypoxemia. Our analyses revealed a 4-lipid signature (including oxidized ceramide OxCer(40:6) and three unknown lipids) that provided an accuracy of 0.80 (95% CI: 0.71–0.89) in the detection of severe OSA. These lipids increased the discriminative power of the STOP-Bang questionnaire in terms of the area under the curve (AUC) from 0.61 (0.50–0.74) to 0.85 (0.71–0.93). CONCLUSIONS: Our results reveal a CSF lipidomic fingerprint that allows the identification of AD patients with severe OSA. Our findings suggest that an increase in central nervous system lipoxidation may be the principal mechanism underlying the association between OSA and AD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01278-7. BioMed Central 2023-08-07 /pmc/articles/PMC10408111/ /pubmed/37550750 http://dx.doi.org/10.1186/s13195-023-01278-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Dakterzada, Farida Benítez, Iván D. Targa, Adriano Carnes, Anna Pujol, Montse Jové, Mariona Mínguez, Olga Vaca, Rafi Sánchez-de-la-Torre, Manuel Barbé, Ferran Pamplona, Reinald Piñol-Ripoll, Gerard Cerebrospinal fluid lipidomic fingerprint of obstructive sleep apnoea in Alzheimer’s disease |
title | Cerebrospinal fluid lipidomic fingerprint of obstructive sleep apnoea in Alzheimer’s disease |
title_full | Cerebrospinal fluid lipidomic fingerprint of obstructive sleep apnoea in Alzheimer’s disease |
title_fullStr | Cerebrospinal fluid lipidomic fingerprint of obstructive sleep apnoea in Alzheimer’s disease |
title_full_unstemmed | Cerebrospinal fluid lipidomic fingerprint of obstructive sleep apnoea in Alzheimer’s disease |
title_short | Cerebrospinal fluid lipidomic fingerprint of obstructive sleep apnoea in Alzheimer’s disease |
title_sort | cerebrospinal fluid lipidomic fingerprint of obstructive sleep apnoea in alzheimer’s disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408111/ https://www.ncbi.nlm.nih.gov/pubmed/37550750 http://dx.doi.org/10.1186/s13195-023-01278-7 |
work_keys_str_mv | AT dakterzadafarida cerebrospinalfluidlipidomicfingerprintofobstructivesleepapnoeainalzheimersdisease AT benitezivand cerebrospinalfluidlipidomicfingerprintofobstructivesleepapnoeainalzheimersdisease AT targaadriano cerebrospinalfluidlipidomicfingerprintofobstructivesleepapnoeainalzheimersdisease AT carnesanna cerebrospinalfluidlipidomicfingerprintofobstructivesleepapnoeainalzheimersdisease AT pujolmontse cerebrospinalfluidlipidomicfingerprintofobstructivesleepapnoeainalzheimersdisease AT jovemariona cerebrospinalfluidlipidomicfingerprintofobstructivesleepapnoeainalzheimersdisease AT minguezolga cerebrospinalfluidlipidomicfingerprintofobstructivesleepapnoeainalzheimersdisease AT vacarafi cerebrospinalfluidlipidomicfingerprintofobstructivesleepapnoeainalzheimersdisease AT sanchezdelatorremanuel cerebrospinalfluidlipidomicfingerprintofobstructivesleepapnoeainalzheimersdisease AT barbeferran cerebrospinalfluidlipidomicfingerprintofobstructivesleepapnoeainalzheimersdisease AT pamplonareinald cerebrospinalfluidlipidomicfingerprintofobstructivesleepapnoeainalzheimersdisease AT pinolripollgerard cerebrospinalfluidlipidomicfingerprintofobstructivesleepapnoeainalzheimersdisease |